chemXplore tracks 4 projects in Greece, of which one is active.
Owners and developers: Hellenic Gas Transmission System Operator S.A. (1)
Licensors are recorded on this project For subscribers
Targeting: Natural gas (1)
FDA clears once‑weekly basal insulin that reduces injection frequency vs daily therapy; Phase 3 QWINT trials in >3,400 adults showed non‑inferior A1C vs glargine and degludec.
SAF reached 1.1 Mt (2.8% share), a near sixfold rise from 2024; supplied at 121 airports, 84% produced in the EU, and 18 Member States host production projects.
6 LNG cargoes/year (~0.6 bcma) for five years from 2027 to boost supply diversification and regional energy resilience.
€2.5bn from the Modernisation Fund supports 51 projects across 11 lower-income EU states to modernise energy systems, expand renewables and cut greenhouse-gas emissions.
Orforglipron produced meaningful body‑weight and waist reductions across menopausal stages in ATTAIN‑1 and ATTAIN‑2, including women with type 2 diabetes.
CRCF Days launched rollout: certification schemes may seek CRCF recognition; Buyers’ Club to aggregate demand; removals and carbon‑farming methodologies near adoption; financing and de‑risking needed
Selected projects across seven EEA countries will add ~1.1 GW electrolyser capacity, produce >1.3 Mt H2 over 10 years, avoid ~9 Mt CO2e; premiums €0.57–€3.49/kg; Spain/Germany add €1.7bn
siRNA blocking APOC3 cut triglycerides 80% vs 17% in trial; lowered acute pancreatitis rates; given subcutaneously every 3 months; common AEs: hyperglycaemia, headache, nausea.
ACHIEVE-4: Foundayo non-inferior vs insulin glargine for MACE-4 (HR 0.84); improved A1C (-1.6 vs -1.0) and weight (-8.8% vs +1.7%) at 52 wks; 57% lower all-cause death; GI AEs; FDA filing planned.
Oral GLP‑1 produced ~12% mean weight loss (~27 lb) at 72 weeks in Phase 3. Available via direct home delivery with low‑cost copays; carries thyroid tumor and GI side‑effect warnings.
